Pegloticase

N/A

Report date: 2026/05/22 20:01:29
First In Class

Base Information

Drug NamePegloticase
Drug Alias Name培戈洛酶pegloticasumMethoxypolyethylene glycol uricase培罗替卡酶培尿酸酶 +[13] 
ClassificationBiologics > Protein drugs > Enzyme > Recombinant enzymeBiologics > Protein drugs > Recombinant protein > Recombinant enzyme
Mechanisms of ActionUric acid stimulants
TargetsUric acid
Therapy Area/IndicationsHyperuricemiaDiabetes ComplicationsDiabetes Mellitus, Type 2 +[7] 
Global Approved IndicationsGout
Approved Indications in ChinaN/A
Original Approved Country/TerritoryUnited States
Original Approved Date2010/09/14
Country/TerritoryCanadaUnited StatesMexico +[5] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesCrealta Pharmaceutical
China Registration ClassN/A

Develop Information

Active CompaniesHorizon PharmaUniversity Of Colorado DenverShanghai Institute of Biological Products Co Ltd
Inactive CompaniesCrealta Pharmaceuticals Ireland LtdSavient Pharmaceuticals Inc
Active IndicationsHyperuricemiaDiabetes ComplicationsDiabetes Mellitus, Type 2 +[6] 
Inactive IndicationsRenal Insufficiency, Chronic

Other Information

ATC CodeM04AX02
Related LinksWikipediaDrugBankKEGG